BSD Medical Signs Exclusive Agreement with ADA Medikal for Distribution of the MicroThermX® Microwave Ablation Line of Products

  BSD Medical Signs Exclusive Agreement with ADA Medikal for Distribution of
  the MicroThermX® Microwave Ablation Line of Products in Turkey

Business Wire

SALT LAKE CITY -- October 18, 2012

BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a
leading provider of medical systems that utilize heat therapy to treat cancer,
announced today that the Company has signed an exclusive agreement with ADA
Medikal (ADA) for the sale and distribution of the MicroThermX^® Microwave
Ablation (MicroThermX^®) line of products in Turkey. ADA is a leading medical
specialty distributor in Turkey with offices in the major metropolitan areas.
ADA has an excellent track record in launching new products and technologies
into the Turkish market. ADA represents a number of major medical device
companies and sells strategically adjacent products to the same clinicians
targeted for the MicroThermX^®.

Turkey is an important international market with a population of more than 73
million and the world's 15^th largest economy. Turkey's location at the
crossroads of Europe and Asia and its growing economy have led to its
recognition as a regional power in the Middle East. ADA Medikal’s sales and
distribution network will ensure that a dedicated team of medically trained
sales representatives are presenting the advantages of the MicroThermX^® to
interventional oncologists throughout Turkey.

About the MicroThermX^® Microwave Ablation System

The MicroThermX^® is a compact, mobile, state-of-the-art, proprietary system
that includes a microwave generator, single-patient-use disposable antennas,
and a thermistor-based temperature monitoring system. The innovative design of
the MicroThermX^® is the first of its kind that allows delivery of higher
power levels using a single generator. The MicroThermX^® utilizes innovative
synchronous phased array technology that was developed and patented by BSD to
provide larger and more uniform zones of ablation during a single procedure.
The MicroThermX^® introduces into the Company’s product line innovative,
high-end disposables (SynchroWave antennas) that are used in each ablation
treatment and will provide a significant ongoing revenue stream. The soft
tissue ablation world market potential is estimated to exceed $2.3 billion.
The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k)
clearance to market the MicroThermX^® for ablation of soft tissue. BSD has
also received CE Marking for the MicroThermX^® System, which allows BSD to
market the MicroThermX^® in Europe. CE Marking is also recognized in many
countries outside of the EU, providing BSD the ability to market the
MicroThermX^® to a number of international markets.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy, which is delivered
using focused radiofrequency (RF) and microwave energy. BSD’s product lines
include both hyperthermia and ablation treatment systems. BSD’s hyperthermia
cancer treatment systems, which have been in use for several years in the
United States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to employ precision-guided microwave energy to ablate
(destroy) soft tissue. The Company has developed extensive intellectual
property, multiple products in the market and established distribution in the
United States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States, Europe and
China. For further information visit BSD Medical's website at
www.BSDMedical.com.

Statements contained in this press release that are not historical facts are
forward-looking statements, as defined in the Private Securities Litigation
Reform Act of 1995. All forward-looking statements are subject to risks and
uncertainties detailed in the Company's filings with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date on which such statements are made, and the Company undertakes no
obligation to update such statements to reflect events or circumstances
arising after such date.

Contact:

BSD Medical Corporation
Dennis Gauger, 801-972-5555
fax: 801-972-5930
investor@bsdmc.com
 
Press spacebar to pause and continue. Press esc to stop.